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Abstract
Background: Hedgehog (Hh) signaling pathway is involved in regulation of many tissues development and
oncogenesis. Recently, Hh signaling has been identified as a required functional pathway for leukemia stem cells
(LSCs), and loss of this pathway impairs leukemia progression.
Objectives: The aim of this study was to determine the expression of Hedgehog signaling molecules in Chronic
Myelogeneous Leukemia (CML) patients and normal people by semiquantitative polymerase chain reaction (PCR)
and to correlate mRNA expression to patients’ clinical data.
Results: Here, we showed that Sonic hedgehog (Shh), Smoothened (Smo), and Gli1 genes of Hh signaling were
significantly upregulated in CML patients when compared with normal people (P < 0.001). The levels of Shh, Smo
mRNA in chronic phase of CML patients were obviously lower than that in blast crisis (p < 0.05). There were no
significant differences of Shh, Ptch1, Smo, Gli1 mRNA expression found when comparing CML patients of chronic
phase(CP) with imatinib(IM) treated or not(p > 0.05).
Conclusions: These findings suggested that activation of the Hh pathway maybe associated with CML progression.
Treatment of CML with imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase inhibitor, has no significant
influence on the inhibition of Hh pathway of CML-CP patients.
Introduction
Chronic myelogeneous leukemia (CML) is a clonal dis-
ease that originates from a single transformed hemato-
poietic stem cell (HSC) or multipotent progenitor cell
harboring a chromosomal translocation between chro-
mosome 9 and 22 [t(9;22)(q34;q11)], resulting in the for-
mation of Philadelphia(Ph) chromosome and at the
molecular level, a chimeric gene known as BCR-ABL
responsible for CML initiation. CML often initiates in a
chronic phase, and without intervention, eventually pro-
gresses to a terminal blastic phase. The introduction of
imatinib mesylate, has revolutionized the disease man-
agement. However, imatinib does not cure CML, and
one of the reasons is that imatinib does not kill leuke-
mia stem cells (LSCs) in CML [1,2]. Recent studies sug-
gest that developmental pathway like Hedgehog
signaling pathway played a role during the expansion of
BCR-ABL-positive leukemic stem cells [3,4]. Hedgehog
ligands (Sonic hedgehog [Shh], Indian hedgehog [Ihh],
and Desert hedgehog [Dhh]) produced by stroma cells
bind to the seven-transmembrane domain receptor
Patched (Ptch), thereby alleviating patched-mediated
suppression of smoothened (Smo), a putative seven-
transmembrane protein. This results in a conformational
change of Smo and subsequent activation of the path-
way, leading to induction of the Gli transcription factors
and transcription of target genes like Ptch1, cyclin D1,
and Bcl2 [5-7]. This study shows the expression and sig-
nificance of Hh signaling pathway target genes Shh,
Ptch1, Smo and Gli1 in patients with CML.
Materials and methods
Samples
Sixty cases of CML treated at West China Hospital of
Sichuan University were included in this study from May
2009 to January 2010.The diagnosis of CML was estab-
lished on the basis of WHO Guideline. The positive
results of both cytogenetic evaluation of t(9;22) and
molecular study of BCR-ABL are required for the diagno-
sis. According to the WHO classification, CML patients
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accelerated phase (AP) and blast crisis (BC). In addition,
38 CML-CP patients were divided into two groups: 31
treated with imatinib,7 treated with hydroxycarbamide
and IFNa (see Table 1). This study also includes 25
healthy donors. Mononuclear cells were obtained by BM
aspiration after obtaining informed consent. The study
was approved by the Sichuan University institution
review board.
RNA isolation
Total RNA was extracted from mononuclear cells using
an RNA extraction kit from Invitrogen according to the
manufacturer’s instruction(Carlsbad, CA, USA).RNA
quality was determined by agarose gel electrophoresis
and quantified spectroscopically(260 nm) using a Bio-
photometer (Eppendorf, Hamburg, Germany).
Reverse-transcription PCR
Complimentary DNA was synthesized from 2 μgo ft o t a l
RNA from each samples using RNA PCR Kit (AMV)
(Promega, Madison, WI). Commercially synthesized PCR
primers were used to amplify specific Hh transcripts:
Shh(F:5’-CCTCGCTGCTGGTATGCTCGGGACT-3’,
R:5’-CTCTGAGTCATCAGCCTGTCCGCTC-3’);Ptch1:
(F:5’-GCACTACTTCAGAGACTGGCTTC-3’,R : 5 ’-AGA
AAGGGAACTGGGCATACTC-3’);Smo(F:5’-ACCCCG
GGCTGCTGAGTGAGAAG-3’,R : 5 ’-TGGGCCCAGGC
AGAGGAGACATC-3’);Gli-1(F:5’-TCCTACCAGAGT
CCCAAGTTTC-3’,R : 5 ’-CCAGAATAGCCACAAAGT
CCAG-3’); b-Actin(F:5’-CCAAGGCCAACCGCGAGAA
GATGAC-3’,R : 5 ’-AGGGTACATGGTGGTGCCGCCA
GAC-3’).
The predicted sizes of the PCR products were 262 bp for
Shh,395 bp for Ptch1,562 bp for Smo,391 bp for Gli-1 and
587 bp for b-Actin.PCR reaction mixtures contained 1 ul
cDNA,3 ul Mgcl2 (25 mM),4 ul dNTP(2.5mM),10×PCR
Buffer 5 ul,0.5 umol of each primer and 1.25 units of
heat-stable DNA polymerase(Takara, Biotech, Japan).
Amplification programmes were applied for Shh(25 cycles
at 94°C,65°C and 72°C,45 s each), Ptch1(28 cycles at 94°
C,30 sec;60°C,30 sec;72°C,45 s), Smo(28 cycles at 94°C,30
sec;55°C 30 sec;72°C,45 s), Gli-1(30 cycles at 94°C, 30 sec;
57°C,30 sec; 72°C,45 s). Four independent PCR reactions
were carried out with different numbers of PCR cycles
thus ensuring that each PCR amplification was not reach
the plateau phase. Subseqently,5 ul PCR product was sub-
jected to 1.5% agarose gel electrophoresis followed by ethi-
dium bromide staining. The density of PCR products were
measured by Bio-Rad gel imaging system(Bio-Rad, USA)
of photographs of ethidium-bromide-stained agarose gels.
The relative gene expression of Shh, Ptch1, Smo, Gli1
were determined by comparing the ratio of PCR products
of the target cDNA segments and the b-Actin cDNA
segment as a reference.
Statistical analysis
The data are presented as means ± SEM. The differ-
ences between the mean values of two groups were
evaluated by using the Student’s t-test (unpaired com-
parison). For comparison of more than three groups, we
used one-way analysis of variance (ANOVA) test fol-
lowed by Tukey’s multiple comparison. P values of
<0.05 were considered statistically significant.
Results
Increased Hh target gene expression in CML
We examined expression of Hh and its receptors in
CML and normal controls by semiquantitative PCR.
Shh, Ptch1, Smo, Gli1 mRNA can be detected in both
CML group and normal control group. We analyzed the
relative expression levels of Shh, Ptch1, Smo, Gli1
mRNA in all groups, and the results indicated that Shh,
Smo, Gli1 mRNA levels in CML group were signifi-
cantly higher than those in control group(p < 0.005).
But there is no significant difference for the mRNA
expression of Ptch1 between CML group and normal
control group(p > 0.05)(see Figure 1).
Expression of Hh and its receptors in different
phases of CML
Further analysis of the data revealed an association of
Hh signaling activation with progression of CML. We
compared the transcript levels of Hh and its receptors
in patients with CML in chronic phase, accelerated
phase and blast crisis. The levels of Shh mRNA in
patients of CML-CP were obviously lower than that of
CML-AP or CML-BC(p < 0.05), but there were no sig-
nificant differences between CML-AP group and CML-
BC group. Our results also demonstrated elevated Smo
expression in patients of CML-BC. The relative expres-
sion levels of Smo mRNA in CML-BC group were
Table 1 Patients characteristics
Patient Characteristic n
Sex
Male 43
Female 17
Phase
CML-CP 38
CML-AP 9
CML-BC 13
Treatment of CML-CP
With imatinib 31
Without imatinib 7
Abbreviations: AP: accelerated phase; BC: blast crisis;
CP: chronic phase;CML:Chronic Myelogeneous Leukemia.
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differences were found between CML-CP and CML-AP
group, CML-AP and CML-BC group. Moreover, in
most of the cases, increased levels of Shh were consis-
tent with elevated levels of Smo expression. We also
found high Gli1 and Ptch1 transcripts in patients of
CML-BC and CML-AP compared with the CML-CP
group, but there were no significant differences between
these three groups(p > 0.05)(see Figure 2).
Expression of Hh and its receptors in CML-CP patients
with IM administered or not
It is reported that expansion of BCR-ABL-positive leu-
kemic stem cells and the maintenance of self-renewal
properties in this population are dependent on intact
and activated Hh signaling, therefore, it is intriguing to
postulate that imatinib have no role on Hh pathway. To
test this possibility, we analyzed the levels of Shh, Ptch1,
Smo, and Gli1 expression in 38 CML-CP patients, with
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Figure 1 Expression of Hh and its receptors in CML patients and normal control. Lane 1:normal control 1:Lane 2:normal control 2:Lane 3:
CML-CP case 1:Lane 4:CML-CP case 2:Lane 5:CML-AP case 1:Lane 6:CML-AP case 2:Lane7:CML-BC case 1:Lane8: CML-BC case 2.
Figure 2 Comparison of Hh and its receptors expression between different groups.
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treated with hydroxycarbamide and IFNa. As expected,
we found that there were no significant differences of
Shh, Ptch1, Smo, Gli1 mRNA expression when compar-
ing CML-CP patients with IM treated or not(p > 0.05)
(see Table 2).
Discussion
Hedgehog signaling pathway is important in the patho-
genesis of several malignancies. Several mechanisms
have been described that lead to the activation of the
Hh signaling pathway in tumor cells, such as activating
point mutations of Smo or inactivating point mutations
in Ptch1 or SUFU [8-12]. Although inappropriate activa-
tion of the Hh signaling pathway has been shown in
many cancers, the assessment of the contribution of Hh
signaling pathway has not been thoroughly examined in
hematologic malignancies. Given the parallels in Hh sig-
naling between regulation of proliferation of primitive
human hematopoietic cells and hematologic malignan-
cies [13-15], we examined whether Hh signaling might
also have a role in CML.
Here, with the use of semiquantitative PCR analysis, we
showed that the Hh signaling components Shh, Ptch1,
Smo and Gli1 were expressed in all CML patients that
we screened. And the relative expression levels of Shh,
Smo, and Gli1 mRNA in CML group were significantly
higher than those in normal control group, suggesting
that activation of the Hh pathway is quite common in
CML. But the level of Ptch1 mRNA in CML and normal
control group did not show significant difference. We
repeated the amplification procedure several times, but
there was still no difference found. The reason might be
that the primary CD34
+ leukemic cells have been not
separated. Furthermore, we found elevated Shh, Ptch1,
Smo, Gli1 transcripts in advanced stages of CML,
especially the levels of Shh, Smo expression were signifi-
cantly higher in blast crisis than that in chronic phase of
CML. A significant correlation between increased expres-
sion of both Shh and Smo in patients of CML-BC would
support the hypothesis that aberrant Hh signaling contri-
butes to CML development or progression.
The outcome for CML patients has been dramatically
improved with the use of tyrosine kinase inhibitors
(TKIs), leading to response rates of greater than 95%
[16]. Although it is very effective in treating chronic
phase CML patients, imatinib will unlikely provide a
cure to these patients. Several reports indicate that dis-
continuation of imatinib treatment even in patients who
have already achieved molecular response induces a
relapse of the disease [17], and therefore, patients are
forced to undergo lifelong therapy. Further studies have
demonstrated that imatinib effectively eradicates Bcr-
Abl-positive progenitor cells but does not target Bcr-
Abl-positive CD34+ LSCs [1,2], as there is evidence that
Bcr-Abl-positive LSCs remain present in the patient’s
bone marrow even after years of therapy and can cause
relapse of disease [18-20]. Our study indicated that ima-
tinib treatment has no significant influence on the inhi-
bition of Hedgehog pathway of CML-CP patients.
Although responses to interferon-alpha (IFNa)a r e
slower and less dramatic than those to imatinib, they
can be durable even after discontinuation of the drug
[21-23]. Unlike imatinib, the specific mechanisms
responsible for IFN’s clinical activity in CML are
unknown. Previous report indicated that IFNa inhibits
Mek phosphorylation in hedgehog pathway activated
basal cell carcinoma (BCC) cells [24]. At the current
time, there is still much to learn about the role of Hh
signaling pathway in the development and progression
of CML, and further studies will be required to under-
stand the biological function(s) of IFNa in the Hh
pathway.
In conclusion, we confirmed variable abnormalities of
Hedgehog pathway activation in CML cases involved in
this study, raising a possibility that combinations of ABL
and Hh inhibitors might offer a new treatment strategy
in CML and might help to effectively cure this disease.
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Table 2 Expression of Hh and its receptors in CML-CP
patients with IM administered or not
CML-CP n Expression
level(°C ± S)
P value
Shh
Without Imatinib 7 0.55 ± 0.020 0.24
With Imatinib 31 0.46 ± 0.017
Ptch1
Without Imatinib 7 1.21 ± 0.031 0.12
With Imatinib 31 0.87 ± 0.031
Smo
Without Imatinib 7 0.66 ± 0.020 0.88
With Imatinib 31 0.59 ± 0.023
Gli1
Without Imatinib 7 0.83 ± 0.042 0.43
With Imatinib 31 0.73 ± 0.027
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